Management of Unresectable T4b Esophageal Cancer

Taylor R. Cushman, Sherif G. Shaaban, Amy C. Moreno, Chi Lin, Vivek Verma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Patients with unresectable cT4b esophageal cancer (EC) are rare and largely excluded from prospective trials. As a result, current treatment recommendations are based on limited evidence. This study sought to evaluate national practice patterns and outcomes for this population and evaluated 3 primary cohorts: patients receiving chemotherapy (CT) with or without subtherapeutic radiotherapy (RT), definitive chemoradiotherapy (CRT), or CT with or without RT followed by definitive surgery. Materials and Methods: The National Cancer Data Base was queried for cT4b N any M0 EC. Exclusion criteria were patients with unspecified staging, palliative treatment, improper, or no histologic confirmation, or lack of CT. Multivariable logistic regression determined factors predictive of receiving surgical therapy. Kaplan-Meier analysis evaluated overall survival (OS), and Cox proportional hazards modeling determined variables associated with OS. Results: Altogether, 519 patients met inclusion criteria; 195 (38%) underwent CT, 291 (56%) underwent definitive CRT, and 33 (6%) underwent surgical-based therapy. Surgery was more likely performed in patients residing in rural areas, living farther from the treating facility, and N1 status (P<0.05 for all). Median OS in the respective cohorts were 6.0, 12.7, and 43.9 months (P<0.001). On multivariate Cox proportional hazards modeling, among others, nonsurgical treatment was associated with poorer OS (P<0.05 for both). Conclusions: In the largest study to date evaluating patterns of care for cT4b EC, as compared with CT alone, addition of definitive RT was associated with higher OS. Although causation is clearly not implied, well-selected responders to CT and/or RT may be able to undergo resection and numerically prolonged survival, but patient selection remains paramount.

Original languageEnglish (US)
Pages (from-to)154-159
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume42
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Esophageal Neoplasms
Drug Therapy
Survival
Radiotherapy
Chemoradiotherapy
Kaplan-Meier Estimate
Therapeutics
Palliative Care
Causality
Patient Selection
Logistic Models
Databases
Population
Neoplasms

Keywords

  • chemotherapy
  • esophageal cancer
  • esophagectomy
  • radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Management of Unresectable T4b Esophageal Cancer. / Cushman, Taylor R.; Shaaban, Sherif G.; Moreno, Amy C.; Lin, Chi; Verma, Vivek.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 42, No. 2, 01.02.2019, p. 154-159.

Research output: Contribution to journalArticle

Cushman, Taylor R. ; Shaaban, Sherif G. ; Moreno, Amy C. ; Lin, Chi ; Verma, Vivek. / Management of Unresectable T4b Esophageal Cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2019 ; Vol. 42, No. 2. pp. 154-159.
@article{7ebfa66e93e4472296e2de3981bb548a,
title = "Management of Unresectable T4b Esophageal Cancer",
abstract = "Purpose: Patients with unresectable cT4b esophageal cancer (EC) are rare and largely excluded from prospective trials. As a result, current treatment recommendations are based on limited evidence. This study sought to evaluate national practice patterns and outcomes for this population and evaluated 3 primary cohorts: patients receiving chemotherapy (CT) with or without subtherapeutic radiotherapy (RT), definitive chemoradiotherapy (CRT), or CT with or without RT followed by definitive surgery. Materials and Methods: The National Cancer Data Base was queried for cT4b N any M0 EC. Exclusion criteria were patients with unspecified staging, palliative treatment, improper, or no histologic confirmation, or lack of CT. Multivariable logistic regression determined factors predictive of receiving surgical therapy. Kaplan-Meier analysis evaluated overall survival (OS), and Cox proportional hazards modeling determined variables associated with OS. Results: Altogether, 519 patients met inclusion criteria; 195 (38{\%}) underwent CT, 291 (56{\%}) underwent definitive CRT, and 33 (6{\%}) underwent surgical-based therapy. Surgery was more likely performed in patients residing in rural areas, living farther from the treating facility, and N1 status (P<0.05 for all). Median OS in the respective cohorts were 6.0, 12.7, and 43.9 months (P<0.001). On multivariate Cox proportional hazards modeling, among others, nonsurgical treatment was associated with poorer OS (P<0.05 for both). Conclusions: In the largest study to date evaluating patterns of care for cT4b EC, as compared with CT alone, addition of definitive RT was associated with higher OS. Although causation is clearly not implied, well-selected responders to CT and/or RT may be able to undergo resection and numerically prolonged survival, but patient selection remains paramount.",
keywords = "chemotherapy, esophageal cancer, esophagectomy, radiation therapy",
author = "Cushman, {Taylor R.} and Shaaban, {Sherif G.} and Moreno, {Amy C.} and Chi Lin and Vivek Verma",
year = "2019",
month = "2",
day = "1",
doi = "10.1097/COC.0000000000000499",
language = "English (US)",
volume = "42",
pages = "154--159",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Management of Unresectable T4b Esophageal Cancer

AU - Cushman, Taylor R.

AU - Shaaban, Sherif G.

AU - Moreno, Amy C.

AU - Lin, Chi

AU - Verma, Vivek

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Purpose: Patients with unresectable cT4b esophageal cancer (EC) are rare and largely excluded from prospective trials. As a result, current treatment recommendations are based on limited evidence. This study sought to evaluate national practice patterns and outcomes for this population and evaluated 3 primary cohorts: patients receiving chemotherapy (CT) with or without subtherapeutic radiotherapy (RT), definitive chemoradiotherapy (CRT), or CT with or without RT followed by definitive surgery. Materials and Methods: The National Cancer Data Base was queried for cT4b N any M0 EC. Exclusion criteria were patients with unspecified staging, palliative treatment, improper, or no histologic confirmation, or lack of CT. Multivariable logistic regression determined factors predictive of receiving surgical therapy. Kaplan-Meier analysis evaluated overall survival (OS), and Cox proportional hazards modeling determined variables associated with OS. Results: Altogether, 519 patients met inclusion criteria; 195 (38%) underwent CT, 291 (56%) underwent definitive CRT, and 33 (6%) underwent surgical-based therapy. Surgery was more likely performed in patients residing in rural areas, living farther from the treating facility, and N1 status (P<0.05 for all). Median OS in the respective cohorts were 6.0, 12.7, and 43.9 months (P<0.001). On multivariate Cox proportional hazards modeling, among others, nonsurgical treatment was associated with poorer OS (P<0.05 for both). Conclusions: In the largest study to date evaluating patterns of care for cT4b EC, as compared with CT alone, addition of definitive RT was associated with higher OS. Although causation is clearly not implied, well-selected responders to CT and/or RT may be able to undergo resection and numerically prolonged survival, but patient selection remains paramount.

AB - Purpose: Patients with unresectable cT4b esophageal cancer (EC) are rare and largely excluded from prospective trials. As a result, current treatment recommendations are based on limited evidence. This study sought to evaluate national practice patterns and outcomes for this population and evaluated 3 primary cohorts: patients receiving chemotherapy (CT) with or without subtherapeutic radiotherapy (RT), definitive chemoradiotherapy (CRT), or CT with or without RT followed by definitive surgery. Materials and Methods: The National Cancer Data Base was queried for cT4b N any M0 EC. Exclusion criteria were patients with unspecified staging, palliative treatment, improper, or no histologic confirmation, or lack of CT. Multivariable logistic regression determined factors predictive of receiving surgical therapy. Kaplan-Meier analysis evaluated overall survival (OS), and Cox proportional hazards modeling determined variables associated with OS. Results: Altogether, 519 patients met inclusion criteria; 195 (38%) underwent CT, 291 (56%) underwent definitive CRT, and 33 (6%) underwent surgical-based therapy. Surgery was more likely performed in patients residing in rural areas, living farther from the treating facility, and N1 status (P<0.05 for all). Median OS in the respective cohorts were 6.0, 12.7, and 43.9 months (P<0.001). On multivariate Cox proportional hazards modeling, among others, nonsurgical treatment was associated with poorer OS (P<0.05 for both). Conclusions: In the largest study to date evaluating patterns of care for cT4b EC, as compared with CT alone, addition of definitive RT was associated with higher OS. Although causation is clearly not implied, well-selected responders to CT and/or RT may be able to undergo resection and numerically prolonged survival, but patient selection remains paramount.

KW - chemotherapy

KW - esophageal cancer

KW - esophagectomy

KW - radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=85057722328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057722328&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000499

DO - 10.1097/COC.0000000000000499

M3 - Article

C2 - 30499838

AN - SCOPUS:85057722328

VL - 42

SP - 154

EP - 159

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -